BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34225525)

  • 1. Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
    Kaur J; Tuler S; Dasanu CA
    J Oncol Pharm Pract; 2022 Mar; 28(2):442-444. PubMed ID: 34225525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
    Pozzi S; Potenza L; Giusti D; Colaci E; Pioli V; Leonardi G; Maccaferri M; Luppi M; Marasca R
    Am J Case Rep; 2022 Aug; 23():e935941. PubMed ID: 36016481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 6. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
    Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
    J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
    Zhou Y; Lu H; Yang M; Xu C
    Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
    Mehraban Far P; Rullo J; Farmer J; Urton T
    Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
    Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
    Pleyer C; Sun C; Desai S; Ahn IE; Tian X; Nierman P; Soto S; Superata J; Valdez J; Lotter J; Wiestner A
    Leuk Lymphoma; 2020 Oct; 61(10):2375-2382. PubMed ID: 32508208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
    Kreiniz N; Bejar J; Polliack A; Tadmor T
    Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
    Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Campylobacter infection in 4 patients treated with ibrutinib.
    Sorin B; Vigneron J; Fadlallah J; Mondesir J; Fieschi C; Oksenhendler E; Galicier L; Malphettes M
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):849-852. PubMed ID: 35304678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.